Variations of teicoplanin concentrations in neutropenic patients

被引：5

作者：

Gimenez, F

Leblond, V

Nguyen, J

Serrand, P

Binet, JL

Grosset, J

Thuillier, A

机构：

[1] Hop La Pitie Salpetriere, Serv Bacteriol, F-75013 Paris, France

[2] Hop La Pitie Salpetriere, Dept Hematol, F-75013 Paris, France

[3] Hop La Pitie Salpetriere, Serv Pharm Pharmacocinet, F-75013 Paris, France

来源：

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 1997年 / 22卷 / 03期

关键词：

D O I：

10.1046/j.1365-2710.1997.94375943.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The aim of this study was to measure the trough plasma concentrations of teicoplanin in neutropenic patients with a view to optimizing the loading dose. Teicoplanin trough plasma concentrations were followed in 11 neutropenic patients after repeated administration of a 6 mg/kg i.v. bolus. The first three injections were given at 12-h intervals, and the rest every 24 h. Trough plasma concentrations at 48 h varied from 5.6 to 13.1 mg/l. The mean trough plasma concentration-time curve indicated a trend towards accumulation. In conclusion, the loading dose of teicoplanin should be tailored to individual neutropenic patients.

引用

收藏

页码：187 / 190

页数：4

相关论文

共 12 条

[1] EARLY TERMINATION OF A PROSPECTIVE, RANDOMIZED TRIAL COMPARING TEICOPLANIN AND FLUCLOXACILLIN FOR TREATING SEVERE STAPHYLOCOCCAL INFECTIONS [J].

CALAIN, P ;

KRAUSE, KH ;

VAUDAUX, P ;

AUCKENTHALER, R ;

LEW, D ;

WALDVOGEL, F ;

HIRSCHEL, B .

JOURNAL OF INFECTIOUS DISEASES, 1987, 155 (02) :187-191

[2] TEICOPLANIN ADMINISTRATION IN BURN PATIENTS - INFLUENCE OF GRAVITY PARAMETERS [J].

CALLAERT, S ;

LIORET, N ;

DALTEROCHE, H ;

LEVY, M ;

LESAGE, D ;

SAIZY, R .

MEDECINE ET MALADIES INFECTIEUSES, 1995, 25 :796-800

[3] CLINICAL-EVALUATION OF TEICOPLANIN FOR THERAPY OF SEVERE INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA [J].

GLUPCZYNSKI, Y ;

LAGAST, H ;

VANDERAUWERA, P ;

THYS, JP ;

CROKAERT, F ;

YOURASSOWSKY, E ;

MEUNIERCARPENTIER, F ;

KLASTERSKY, J ;

KAINS, JP ;

SERRUYSSCHOUTENS, E ;

LEGRAND, JC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (01) :52-57

[4] EVALUATION OF TEICOPLANIN FOR TREATMENT OF ENDOCARDITIS CAUSED BY GRAM-POSITIVE COCCI IN 20 PATIENTS [J].

LEPORT, C ;

PERRONNE, C ;

MASSIP, P ;

CANTON, P ;

LECLERCQ, P ;

BERNARD, E ;

LUTUN, P ;

GARAUD, JJ ;

VILDE, JL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (06) :871-876

[5] Population pharmacokinetic study of teicoplanin in severely neutropenic patients [J].

Lortholary, O ;

Tod, M ;

Rizzo, N ;

Padoin, C ;

Biard, O ;

Casassus, P ;

Guillevin, L ;

Petitjean, O .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1242-1247

[6] TEICOPLANIN OR VANCOMYCIN IN THE TREATMENT OF GRAM-POSITIVE INFECTIONS [J].

MURPHY, S ;

PINNEY, RJ .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1995, 20 (01) :5-11

[7] TEICOPLANIN PHARMACOKINETICS IN HEALTHY-VOLUNTEERS AFTER ADMINISTRATION OF INTRAVENOUS LOADING AND MAINTENANCE DOSES [J].

OUTMAN, WR ;

NIGHTINGALE, CH ;

SWEENEY, KR ;

QUINTILIANI, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (11) :2114-2117

[8]

PENY AM, 1991, REUN INT CHIM ANT 5, P113

[9] THE DESIGN, ANALYSIS, AND REPORTING OF CLINICAL-TRIALS ON THE EMPIRICAL ANTIBIOTIC MANAGEMENT OF THE NEUTROPENIC PATIENT - REPORT OF A CONSENSUS PANEL [J].

PIZZO, PA ;

ARMSTRONG, D ;

BODEY, G ;

DEPAUW, B ;

FELD, R ;

GLAUSER, M ;

GAYA, H ;

KARP, J ;

KLASTERSKY, J ;

TODESCHINI, G ;

VERHOEF, J ;

WADE, J ;

YOUNG, LS ;

REMINGTON, J .

JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (03) :397-401

[10] CLINICAL PHARMACOKINETICS OF TEICOPLANIN [J].

ROWLAND, M .

CLINICAL PHARMACOKINETICS, 1990, 18 (03) :184-209